CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE 21:00:03 06/11/2026 GMT			5-day change	1st Jan Change
337.52 ^USD	+7.83%		-6.09%	+69.20%

11-05	UBS Adjusts Price Target on Charles River Laboratories International to $387 From $357, Maintains Buy Rating	MT
11-05	Rothschild & Co Redburn Adjusts Price Target on Charles River Laboratories International to $375 From $318	MT

All News

Mentions Relevance

11-05	UBS Adjusts Price Target on Charles River Laboratories International to $387 From $357, Maintains Buy Rating	MT
11-05	Rothschild & Co Redburn Adjusts Price Target on Charles River Laboratories International to $375 From $318	MT
11-05	RBC Raises Price Target on Charles River Laboratories International to $352 From $322, Keeps Outperform Rating	MT
11-05	Deutsche Bank Adjusts Charles River Laboratories International Price Target to $350 From $320, Maintains Buy Rating	MT
11-05	Jefferies Adjusts Price Target on Charles River Laboratories International to $385 From $340	MT
11-04	Charles River Laboratories International, Inc., Q3 2026 Earnings Call, Nov 04, 2026
11-04	Charles River Laboratories International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 26, 2026	CI
11-04	Charles River Laboratories Fiscal Q3 Non-GAAP Earnings Increase, Revenue Falls; Raises 2026 Guidance	MT
11-04	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q3 Revenue $982.7M, vs. FactSet Est of $960.4M	MT
11-04	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q3 Adjusted EPS $3.09 per Share, vs. FactSet Est of $2.97	MT
11-04	Charles River Laboratories Announces Third-Quarter 2026 Results	BU
11-04	Charles River Laboratories International, Inc. Revises Earnings Guidance for the Year 2026	CI
10-27	Charles River Laboratories International, Inc. Announces Collaboration with Ipsen to Leverage Virtual Control Groups in Good Laboratory Practice-Compliant Study	CI
10-27	Charles River Leverages Virtual Control Groups in GLP Studies	BU
10-26	Charles River Laboratories International Insider Sold Shares Worth $8,414,700, According to a Recent SEC Filing	MT
10-22	Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment	BU
10-14	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT
10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI
10-13	Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy	MT
10-13	Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development	BU
10-12	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300	MT
10-09	Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call	BU
10-06	Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform	CI
10-06	Charles River and Autolomous Partner to Transform Laboratory Execution Systems	BU
09-30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT